Side-by-side · Research reference
KPVvsMK-677
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BPhase 2Reviewed13/45 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
MK-677
Oral GHS · Ibutamoren
Oral capsule · 1×/day
01Mechanism of Action
Parameter
KPV
MK-677
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Ghrelin receptor (GHS-R1a)Murphy 1998
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008
Feedback intact?
No melanocortin receptor binding
Pulsatile pattern preserved despite long half-lifeMurphy 1998
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
MK-677
Standard dose
200–500 mcg / day SQ or oralDalle-Pang 2024
10–25 mg / day oralNass 2008
25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.
Frequency
Daily or 2–3× per week
Once daily, oral
Lower / starter dose
100 mcg / day
5 mg / day
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008Murphy 1998
Duration
4–8 weeks per cycle
8–16 weeks per cycle (off-cycle to reset receptor sensitivity)
Reconstitution
Bacteriostatic water (SQ form)
Oral, no reconstitution
Timing
No specific time; often taken with / before meals (oral)
Pre-sleep preferred for natural GH pulse alignment
04Side Effects & Safety
Parameter
KPV
MK-677
Injection site reaction
Mild irritation
—
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
Avoid
Increased appetite
—
Strong appetite increase via ghrelin agonism
Water retention
—
Mild edema, paresthesias
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Cardiovascular
—
No clear adverse signal in trials; congestive heart failure caution
Drowsiness
—
Common, especially during initial weeks
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
MK-677
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
- ·Congestive heart failure (caution)
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
MK-677
- ·Untreated diabetes
- ·Pre-diabetes
- ·Severe insulin resistance
05Administration Protocol
Parameter
KPV
MK-677
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Capsule or oral solution. No injection.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
Oral. Take with or without food.
3. Timing
Morning preferred; oral form taken with / before meals.
Pre-sleep preferred — aligns with natural GH pulse.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Capsule: room temp ≤25 °C, dry place.
5. Needle
29–31G insulin syringe (SQ form).
Monitor HbA1c every 8–12 weeks during chronic use.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
MK-677
— no documented stacks